|
Market Closed -
NYSE
21:00:02 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 164.77 USD | +1.94% |
|
+0.15% | +79.23% |
| 09-03 | UK stocks rise as bond rally lifts risk sentiment | RE |
| 09-03 | AstraZeneca Kept at Buy as Berenberg Notes Upcoming COPD Data Readout | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 255,019 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -11.39% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 274,481 | 266,807 | 258,296 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -11.8% | -2.8% | -3.19% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 21.2x | 18.5x | 16.1x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.73x | 4.2x | 3.57x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.3x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.03x | 3.82x | 3.58x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.34x | 3.99x | 3.62x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.4x | 11x | 9.64x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13x | 11.5x | 10.1x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 29.2x | 20.4x | 17.5x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.43% | 4.89% | 5.7% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.339 | 3.561 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.03% | 2.17% | 2.23% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.773 | 8.884 | 10.22 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43% | 40.1% | 35.8% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,239 | 66,839 | 71,291 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,149 | 24,301 | 26,782 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,073 | 23,284 | 25,554 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,012 | 13,692 | 15,637 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,462 | 11,788 | 3,277 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 164.42 | 164.42 | 164.42 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.01x | 11.99x | 24.31x | 0.6% | 1,034B | |
| 30.97x | - | - | 1.93% | 671B | |
| 33.21x | 7.7x | 16x | 2.64% | 460B | |
| 19.86x | 4.73x | 11.71x | 2.8% | 353B | |
| 23.09x | 5.93x | 14.7x | 2.69% | 309B | |
| 21.15x | 4.34x | 12.39x | 2.03% | 255B | |
| 28.09x | 7.23x | 12.82x | 2.27% | 240B | |
| 13.44x | 4.86x | 10.14x | 3.75% | 207B | |
| -46.21x | 6.66x | 25.99x | 2.18% | 188B | |
| Average | 17.40x | 6.68x | 16.01x | 2.32% | 412.97B | |
| Weighted average by Cap. | 24.37x | 8.05x | 17.85x | 1.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
